Thrombosis and Inflammation in Vessels Initiative (TIVI)
Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Aug 13, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Thrombosis and Inflammation in Vessels Initiative (TIVI) is a clinical trial that aims to understand how diseases related to the immune system, blood clots, and blood vessels develop and change over time. Researchers are particularly interested in how these conditions can impact different parts of the body, such as the heart and brain. The study is open to people aged 5 years and older who have a blood clot, immune, or vascular disorder, as well as healthy family members and volunteers.
Participants in this study will start with a visit to provide their medical history and undergo a physical exam and blood test. There are many optional tests they can choose from, which may include checks on heart and lung function, imaging scans, and even some mental function tests. Participants can also return for follow-up visits over the next 7.5 years, and some appointments can be done via telehealth. This study is currently recruiting, and it's an opportunity for those affected by these conditions or healthy individuals to contribute to important medical research.
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- • Age \>= 5 years at the time of consent
- • Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document
- In addition, the following cohort-specific inclusion criteria apply:
- Affected Subjects:
- • -Known or possible thrombotic, immune, or vascular disorder after review of the subject s medical records and/or discussion of medical history
- Relatives of Affected Subjects:
- • -Being a relative of an affected subject
- Unrelated Healthy Controls:
- • -In good general health as evidenced by medical history
- EXCLUSION CRITERIA:
- An individual who meets any of the following criteria will be excluded from participation in this study:
- • -Any condition that in the opinion of the Investigator would warrant exclusion
- Unrelated Healthy Controls:
- • Unrelated healthy volunteers who decline to have blood drawn and/or tissue studies or who do not consent to have samples stored for future research
- • Cognitively impaired individuals
About National Heart, Lung, And Blood Institute (Nhlbi)
The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Patients applied
Trial Officials
Yogendra Kanthi, M.D.
Principal Investigator
National Heart, Lung, and Blood Institute (NHLBI)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported